U.S., Dec. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07288567) titled 'A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents' on Dec. 16.
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of KarXT for treatment of Schizophrenia in adolescents.
Study Start Date: Jan. 27, 2026
Study Type: INTERVENTIONAL
Condition:
Schizophrenia
Intervention:
DRUG: KarXT
Specified dose on specified days
OTHER: KarXT Matching Placebo
Specified dose on specified days
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Bristol-Myers Squibb
Disclaimer: Curated by HT Syndication....